

Follow-Up Care for Children Prescribed Attention-Deficit/Hyperactivity Disorder (ADHD) Medication

© Ingenix, Inc. 2011

Confidential

HEDIS is a registered trademark of the National Committee for Quality Assurance (NCQA).

National Committee for Quality Assurance (NCQA) Notice:

HEDIS 2011 Measure Specification.

The HEDIS® measures and specifications were developed by and are owned by the National Committee for Quality Assurance ("NCQA"). The HEDIS measures and specifications are not clinical guidelines and do not establish standards of medical care. NCQA makes no representations, warranties, or endorsement about the quality of any organization or physician that uses or reports performance measures or any data or rates calculated using the HEDIS measures and specifications and NCQA has no liability to anyone who relies on such measures or specifications. ©2010 National Committee for Quality Assurance, all rights reserved.

'NS-H' and 'NSHA' indicate NCQA HEDIS rules.

CP-N and CPNA measures indicate some difference from the national standard specification. Please refer to EBMConnect76CC1HEDISNationalStandardVariation document for a detailed explanation of the differences.

Measure author: NCQA

NQF endorsement status: Endorsed as of January 1, 2010

Specifications for NQF endorsed NCQA HEDIS® measures can be found at:

<http://www.ncqa.org/tabid/59/Default.aspx>

The most current specifications for all NCQA HEDIS® measures can be found at:

<http://www.ncqa.org/tabid/78/Default.aspx#HEDISMD>

CP-N

9000001

Patient(s) with an outpatient, intensive outpatient or partial hospitalization follow-up visit with a prescribing provider during the 30 days after the initial ADHD prescription.

CP-N

9000002

Patient(s) with an outpatient, intensive outpatient or partial hospitalization follow-up visit with a prescribing provider during the 30 days after the initial ADHD prescription, AND two follow-up visits during the 31 days through 300 days after the initial ADHD prescription.